(Total Views: 600)
Posted On: 06/04/2020 11:58:28 AM
Post# of 156228
Re: nmbr1stckpckr #36630
Wouldn't eIND patients now end up enrolling in cydy trials?
I feel like if the FDA wanted to stifle progress on the timing side they would allow them to continue eINDs.
Also the FDA knows about the interim analysis as well as how many eINDS have been approved to date as well as the results. Little late to curb the accumulation of evidence.
Also, knowing NP's aversion for communicating bad news I think if the communication were more to your tone he just wouldn't have said anything.
Lastly, the FDAs preference for enrolling efficacious drug trials is corroborated by the other post I put up. From the CEO of ANSUN maker of DAS181 currently enrolling patients.
Quote to the effect of "FDA frowns on granting compassionate use since scientists don't learn anything".
Respectfully, I don't think your interpretation is really supported by anything other than your perception which is a bit on the paranoid side. Again, respectfully.
I feel like if the FDA wanted to stifle progress on the timing side they would allow them to continue eINDs.
Also the FDA knows about the interim analysis as well as how many eINDS have been approved to date as well as the results. Little late to curb the accumulation of evidence.
Also, knowing NP's aversion for communicating bad news I think if the communication were more to your tone he just wouldn't have said anything.
Lastly, the FDAs preference for enrolling efficacious drug trials is corroborated by the other post I put up. From the CEO of ANSUN maker of DAS181 currently enrolling patients.
Quote to the effect of "FDA frowns on granting compassionate use since scientists don't learn anything".
Respectfully, I don't think your interpretation is really supported by anything other than your perception which is a bit on the paranoid side. Again, respectfully.
(1)
(0)
